It has also been reported that an M-CSFR-neutralizing antibody resulted in both a decrease in atherosclerosis [16] and pharmacologic inhibition of M-CSF signaling via a specific inhibitor of M-CSFR (GW2580), which also resulted in a decrease in atherosclerosis [17,18]. The gene discussed is CSF1; the disease is atherosclerosis.